Neuroendocrine Tumor Treatment Market Set for Strong Growth to USD 10,398.7 Million by 2031, Led by North America's 42% Market Share | DataM Intelligence

The Global Neuroendocrine Tumor Treatment Market reached USD 5,053.2 million in 2022 and is projected to reach USD 10,398.7 million by 2031, growing at a strong CAGR of 9.7% during 2024-2031.

Market growth is fueled by increasing incidence of neuroendocrine tumors, rising adoption of targeted therapies, and advancements in diagnostic imaging technologies. Additionally, growing investments in oncology research and improved availability of advanced treatment options are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neuroendocrine-tumors-treatment-market?ram

United States: Key Industry Developments
✅ October 2025: Viewpoint Molecular Targeting, Inc. received FDA fast-track designation for VMT-α-NET, a radiopharmaceutical targeting SSTR2-positive unresectable or metastatic neuroendocrine tumors, accelerating development for improved patient access to advanced therapies.​

✅ September 2024: Abdera Therapeutics, Inc. secured FDA orphan drug designation for ABD-147, a next-generation precision radiopharmaceutical biologic therapy aimed at treating neuroendocrine carcinoma with enhanced targeting capabilities.

Key Merges and Acquisitions(2025):
✅ Bristol Myers Squibb (BMS) completes acquisition of RayzeBio: In February 2024 (transaction completed in early 2025), BMS finalized its acquisition of RayzeBio for approximately $4.1 billion. This deal significantly strengthens BMS's radiopharmaceutical platform with RYZ101, a lead program targeting SSTR2-positive neuroendocrine tumors (NETs) and small cell lung cancer.

✅ Novartis acquires MorphoSys (Indirect Impact): Novartis completed its acquisition of German biotech MorphoSys in the first half of 2024 for approximately $2.9 billion (€2.7 billion). The primary target was a myelofibrosis drug, but this highlights large pharma's strategy of acquiring innovative oncology pipelines, a trend relevant to the NET market's need for new therapies like PRRT.

✅ Lantheus acquires Life Molecular Imaging (LMI) (Indirect Impact): In January 2025, Lantheus announced plans to acquire LMI for an upfront payment of $350 million. This acquisition boosts Lantheus's diagnostic capabilities in various cancers and includes assets relevant to a diagnostic/therapeutic radiopharmaceutical combination, complementing the neuroendocrine tumor treatment market's focus on radioligand therapies.

Market Segmentation Analysis:
-By Therapy Type: SSAs Dominate with 74% Share
Somatostatin analogs (SSAs) lead with 74% market share in 2024, serving as first-line therapy for controlling symptoms and tumor growth in somatostatin receptor-positive neuroendocrine tumors (NETs).​
Targeted therapy holds a growing portion due to personalized approaches for pancreatic and gastrointestinal NETs, offering better outcomes and fewer side effects.​
Others, including chemotherapy, contribute the remainder but lag behind in adoption.​

-By Indication: Pancreatic NETs at 38.5% Lead
Pancreatic NETs command 38.5% share in 2023, driven by high prevalence and need for intensive treatments like PRRT and surgery.​
Gastrointestinal NETs follow as a key area with rising diagnoses and SSA efficacy.​
Small intestine, lungs, and others (e.g., carcinoid at 24.3%) round out the segments, with lungs showing steady demand.​

-By Route of Administration: Oral Leads Growth
Oral routes dominated in 2023 with strong CAGR of 8.8%, favored for patient convenience in long-term SSA and targeted therapies.​
Parenteral supports complex inpatient needs like infusions but trails in share.​

-By End-User: Hospitals Hold Largest Share
Hospitals captured the top revenue share in 2024 through multidisciplinary teams, advanced diagnostics, and capacity for surgeries/PRRT.​
Clinics and others (e.g., cancer centers) grow via outpatient care but remain secondary.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=neuroendocrine-tumors-treatment-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising global incidence and prevalence of neuroendocrine tumors, driven by aging populations, lifestyle changes like obesity, and improved early detection through advanced imaging.​

-Advancements in targeted therapies, including somatostatin analogs, peptide receptor radionuclide therapy (PRRT), and precision medicines that offer better efficacy and fewer side effects.​

-Increased awareness of the disease, early diagnostics, and government initiatives supporting rare cancer research and orphan drug incentives.​

-Growing adoption of immunotherapies, such as immune checkpoint inhibitors, alongside personalized medicine approaches tailored to tumor genetics.​

-Expansion of innovative technologies like multi-analyte liquid biopsies, genomics, and multi-disciplinary precision oncology trials enhancing treatment outcomes.​

Regional Insights:
-North America leads the Neuroendocrine Tumor Treatment Market with the largest share of 42% as of 2024, driven by advanced healthcare infrastructure, high prevalence of neuroendocrine tumors, and widespread adoption of innovative therapies like somatostatin analogs and peptide receptor radionuclide therapy (PRRT).​

-Europe holds a significant market position, fueled by robust pharmaceutical infrastructure, government funding for research, and increasing access to advanced treatments amid rising tumor incidence rates.​

-Asia Pacific follows with rapid growth potential, propelled by heightened awareness, improved diagnostics, and quick adoption of targeted therapies such as everolimus and sunitinib in key countries like China, Japan, and South Korea.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neuroendocrine-tumors-treatment-market?ram

Key Players:
Pfizer Inc. | Ipsen Pharmaceuticals | Novartis AG | AVEO Pharmaceuticals Inc. | Eli Lilly & Company | CK Hutchison Holdings (HUTCHMED) | Boehringer Ingelheim International GmbH | Lantheus Holdings Inc. | Merck & Co., Inc. | Sanofi

Key Highlights (Top 5 Key Players) for Neuroendocrine Tumor Treatment Market:
-Pfizer, Inc. leads with robust oncology portfolios including somatostatin analogs, contributing significantly to the market valued at USD 2.83 billion in 2025.​

-Novartis AG advances treatments like everolimus for neuroendocrine tumors, supporting sector growth projected to exceed USD 5 billion by 2035.​

-Ipsen Pharmaceuticals drives expansion with therapies such as lanreotide, amid a market CAGR of around 6% through 2034.​

-Eli Lilly & Company bolsters offerings in targeted therapies for NETs, aligning with rising incidence and tech improvements in tumor treatment.​

-Boehringer Ingelheim International GmbH focuses on innovative drug pipelines for neuroendocrine cancers, within a competitive landscape targeting USD 4.89 billion by 2034.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.